Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study

  • Andrzej Wasilewski Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
  • Urszula Krajewska Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Faculty of Pharmacy, Medical University of Lodz, Lodz, Poland
  • Katarzyna Owczarek Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
  • Urszula Lewandowska Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
  • Jakub Fichna Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
Keywords: cannabinoid receptors, Colo-205, colorectal cancer, invasion, migration,


Earlier reports suggest that the endocannabinoids may play a role of endogenous tumor growth modulators. In this study, we investigated whether inhibition of the enzymes involved in the synthesis and degradation of endocannabinoids may reduce colorectal cancer cell invasion and migration. The human colon adenocarcinoma Colo-205 cells were incubated with PF-3845, JZL-184 and RHC-80267 (fatty acid amide hydrolase (FAAH), mono- (MAGL) and diacylglycerol lipase (DAGL) inhibitors, respectively) for 48 h. The MTT colorimetric assay was performed to quantify cell viability. Next, Colo-205 cells were incubated with PF-3845 alone or with PF-3845 together with selected antagonists: AM 251, AM 630, SB 366791, RN 1734 and G-15 (CB1, CB2, TRPV1, TRPV4 and GPR30 antagonists, respectively). Western blot assay was applied to identify the changes in CB1 and CB2 receptor expression. Migration and invasion assays were employed to characterize the effect of PF-3845 on colorectal cancer cell invasion. We found that of all inhibitors used, the FAAH inhibitor PF-3845 reduced most effectively Colo-205 cell line viability (IC50=52.55 μM). We also showed that the effect of reducing cell viability was enhanced when Colo-205 cells were incubated with PF-3845 and RN-1734, a TRPV4 antagonist (IC50=30.54 μM). Western blot assay revealed significantly decreased CB1 receptor expression levels, while CB2 expression was increased in response to PF-3845 compared with control. Furthermore PF-3845 inhibited migration and invasion of Colo-205 cell line. These results suggest that pharmacological inhibition of FAAH and consequent enhancement of the endocannabinoid levels may reduce the colorectal cancer growth and progression.


Alberich Jordà M, Rayman N, Tas M, Verbakel SE, Battista N, van Lom K, Löwenberg B, Maccarrone M, Delwel R (2004) The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104: 526-34. http://doi.org/10.1182/blood-2003-12-4357

Bifulco M, Laezza C, Pisanti S, Gazzerro P (2006) Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148: 123-35. http://doi.org/10.1038/sj.bjp.0706632

Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, DI Marzo V (2004) A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18: 1606-608. http://doi.org/10.1096/fj.04-1754fje

Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C (2006) Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 66: 6615-621. http://doi.org/10.1158/0008-5472.CAN-05-4566

Cianchi F, Papucci L, Schiavone N, Lulli M, Magnelli L, Vinci MC, Messerini L, Manera C, Ronconi E, Romagnani P, Donnini M, Perigli G, Trallori G, Tanganelli E, Capaccioli S, Masini E (2008) Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clin Cancer Res 14: 7691-700. http://doi.org/10.1158/1078-0432.CCR-08-0799

Cipriano M, Haggstrom J, Hammarsten P, Fowler CJ (2013) Association between cannabinoid CB(1) receptor expression and Akt signalling in prostate cancer. PLoS One 8: e65798. http://doi.org/10.1371/journal.pone.0065798

Cudaback E, Marrs W, Moeller T, Stella N (2010) The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS One 5: e8702. http://doi.org/10.1371/journal.pone.0008702

De Lago E, Gustafsson SB, Fernandez-Ruiz J, Nilsson J, Jacobsson SO, Fowler CJ (2006) Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J Neurochem 99: 677-88. . http://doi.org/10.1111/j.1471-4159.2006.04104.x

Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-949.

Ek S, Hogerkorp CM, Dictor M, Ehinger M, Borrebaeck CA (2002) Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 62: 4398-405.

Endsley MP, Aggarwal N, Isbell MA, Wheelock CE, Hammock BD, Falck JR, Campbell WB, Nithipatikom K (2007) Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer 121: 984-91. http://doi.org/10.1002/ijc.22761

Gerard CM, Mollereau C, Vassart G, Parmentier M (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279: 129-34.

Gustafsson SB, Palmqvist R, Henriksson ML, Dahlin AM, Edin S, Jacobsson SO, Öberg Å, Fowler CJ (2011) High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer. PLoS One 6: e23003. http://doi.org/10.1371/journal.pone.0023003

Hansen MB, Nielsen SE, Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-10.

Islam TC, Asplund AC, Lindvall JM, Nygren L, Liden J, Kimby E, Christensson B, Smith CI, Sander B (2003) High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia 17: 1880-890. http://doi.org/10.1038/sj.leu.2403057

Jung CK, Kang WK, Park JM, Ahn HJ, Kim SW, Taek Oh S, Choi KY (2013) Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer. Oncol Lett 5: 870-76. http://doi.org/10.3892/ol.2012.1081

Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 20: 4553-560. http://doi.org/10.1200/JCO.2005.17.749

Laezza C, Pisanti S, Malfitano AM, Bifulco M (2008) The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway. Endocr Relat Cancer 15: 965-74. http://doi.org/10.1677/ERC-08-0030

Lewandowska U, Szewczyk K, Owczarek K, Hrabec Z, Podsędek A, Koziołkiewicz M, Hrabec E (2013) Flavanols from Japanese quince (Chaenomeles japonica) fruit inhibit human prostate and breast cancer cell line invasiveness and cause favorable changes in Bax/Bcl-2 mRNA ratio. Nutr Cancer 65: 273-85. http://doi.org/10.1080/01635581.2013.749292

Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308: 838-45. http://doi.org/10.1124/jpet.103.061002

Matas D, Juknat A, Pietr M, Klin Y, Vogel Z (2007) Anandamide protects from low serum-induced apoptosis via its degradation to ethanolamine. J Biol Chem 282: 7885-892. http://doi.org/10.1074/jbc.M608646200

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-64. http://doi.org/10.1038/346561a0

Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.

Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65. http://doi.org/10.1038/365061a0

Nithipatikom K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ, Campbell WB (2004) 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer invasion. Cancer Res 64: 8826-30. http://doi.org/10.1158/0008-5472.CAN-04-3136

Notarnicola M, Messa C, Orlando A, Bifulco M, Laezza C, Gazzerro P, Caruso MG (2008) Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand J Gastroenterol 43: 66-72.

Pertwee RG (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 30 Suppl 1: S13-S18. http://doi.org/10.1038/sj.ijo.0803272

Ranger JJ, Levy DE, Shahalizadeh S, Hallett M, Muller WJ (2009) Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res 69: 6823-830. http://doi.org/10.1158/0008-5472.CAN-09-1684

Reggio PH, Traore H (2000) Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem Phys Lipids 108: 15-35.

Rudolph MI, Boza Y, Yefi R, Luza S, Andrews E, Penissi A, Garrido P, Rojas IG (2008) The influence of mast cell mediators on migration of SW756 cervical carcinoma cells. J Pharmacol Sci 106: 208-18.

Steward BW, Wild CP (2014) World Cancer Report. World Health Organisation.

Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D (2005) Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144: 1032-36. http://doi.org/10.1038/sj.bjp.0706134